DOI: https://doi.org/10.22141/2224-0721.15.2.2019.166098

Correction of bone remodeling disorders in long-term corticosteroid therapy

Ya.F. Kutasevych, I.O. Oliinyk, I.O. Mashtakova, A.E. Abdalla

Abstract


Background. In severe dermatoses, corticosteroid drugs are usually prescribed for a long period of time, and even for life; therefore, the detection of side effects caused by prolonged use of systemic glucocorticosteroids, in particular bone metabolism disorders, and their prevention are important components of comprehensive therapy for severe dermatoses. Consequently, the development of methods for early diagnosis, treatment and prevention of bone remodeling disorders under the influence of prolonged corticosteroid therapy in patients with severe dermatosis is extremely relevant for modern dermatology. The purpose of the study is to increase the efficiency and safety of treating patients with severe dermatosis by preventing or minimizing the development of side effects in the treatment with glucocorticosteroid hormones. Materials and methods. The study involved 134 patients with severe dermatosis (acantholytic pemphigus, bullous pemphigoid, Dühring disease, erythroderma, etc.). Clinical anamnestic, biochemical, cytological, immunoenzyme, instrumental and statistical methods of research were used. Results. Patients receiving prolonged systemic corticosteroid therapy showed a significant decrease in the bone fraction of alkaline phosphatase — by 2.1 times, in osteocalcin level — by 6.6 times, and 2.2­fold increase in the C­terminal telopeptide. According to ultrasonic densitometry, osteopenia was detected in 35.5 %, osteoporosis — in 64.5 % of patients. Calcium supplements with vitamin D3 and anti­resorptive agent were prescribed to correct bone remodeling. As a result, an increase in these parameters was noted, indicating the restoration of osteosynthesis and normalization of bone tissue resorption processes that was confirmed by 1.8­fold increase in the bone mineral density. To prevent the development of bone remodeling disorders, antiresorptive drugs, calcium and vitamin D3 were administered as a part of comprehensive treatment, in combination with systemic corticosteroids throughout the whole course of therapy. Conclusions. The conducted research has allowed increasing efficiency and safety of treatment of patients with severe dermatosis by preventing or minimizing the development of side effects of glucocorticosteroid treatment.


Keywords


glucocorticosteroids; remodeling; bone tissue; side effects; chronic dermatosis; therapy; prevention

References


Katsambas AD, Lotti TM, Camacho-Martinez FM, et al., authors; Katsambas AD, Lotti TM, editors. European Handbook of Dermatological Treatments. European guidance on treatment of dermatological diseases. Berlin, Germany: Springer; 2003. 804 p.

Bilyayev GM. Modern idea about pathogenesis of psoriatic arthropathy and treatment of these patients. Dermatologіa ta venerologіa. 2010;(47):7-30. (in Russian).

Dudchenko MO, Vasyl'jeva KV, Popova IB, et al. Dermatovenerologija: navchal'nyj posibnyk [Dermatovenereology: study guide]. Poltava; 2011. 319 p. (in Ukrainian).

Voznyak IYa, Svyatenko TV. Studying quality of life of patients suffering psoriatic disease. Dermatovenerologia, kosmetologia, seksopatologia. 2009;(12):273-275. (in Ukrainian).

Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009 Dec;68(12):1833-8. doi: 10.1136/ard.2008.100008.

Syzon OO, Stepanenko VI. Psoriasis arthrоріса: substantiation recommended methods of therapy and prophylaxis: part 1. Ukrainian Journal of Dermatology, Venerology, Cosmetology. 2010;(37):42-50. (in Ukrainian).

Namba S, Yamaoka-Tojo M, Hashikata T, et al. Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis. BBA Clin. 2015 Aug 12;4:76-80. doi: 10.1016/j.bbacli.2015.08.002.

Kravchun NA, Karachentsev IuI, Goncharova OA, Kazakov AV, Gorshunskaia MIu. Dislipidemii pri endokrinnykh zabolevaniiakh [Dyslipidemia in patients with endocrine diseases]. Kharkiv: Prapor; 2008. 224 p. (in Ukrainian).

Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011 Jul;63(1):40-6. doi: 10.1016/j.jdermsci.2011.03.002.

Golovach IJu. Glucocorticoid-induced osteoporosis: the stages of development of studies in Ukraine and modern state of problem. Bolʹ, sustavy, pozvonočnik. 2011;(3):47-53. (in Ukrainian).

Reken M, Shaller M, Zattler E, Burgdorf V. Taschenatlas Dermatologie: Grundlagen, Diagnostik, Klinik. Stuttgart, Germany: Thieme; 2010. 406 p.

Statinova YeA, Omelchenko RYa, Vaskovskaya LS, Sokhin SA. Role of endogenous and exogenous factor in development of osteoporosis in children (review of literature). Travma. 2013;14(5):89-93. doi: 10.22141/1608-1706.5.14.2013.88159. (in Russian).

Povoroznyuk VV, Dzerovych NI. Sarcopenia, osteoporosis and its complications. Bolʹ, sustavy, pozvonočnik. 2016;4(24):7-11. doi: 10.22141/2224-1507.4.24.2016.94620. (in Ukrainian).

Kamyshnikov VS, editor. Klinicheskaia laboratornaia diagnostika: metody i traktovka laboratornykh issledovanii [Clinical laboratory diagnostics: methods and interpretation of laboratory research]. Moscow: MED-press-inform; 2015. 720 p. (in Russian).

Kobzar' AI. Prikladnaia matematicheskaia statistika. Dlia inzhenerov i nauchnykh rabotnikov [Applied mathematical statistics. For engineers and scientists]. 2nd ed. Moscow: FIZMATLIT; 2012. 816 p. (in Russian).






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта